Introduction 93
In therapeutic approaches where the Fc of human IgG1 is critically important, 94 receptor binding and functional properties of the Fc are lost after de-95 glycosylation or removal of the Asn-297 N-linked glycosylation attachment site 96 to multiple glycan receptors that control excessive inflammation by IVIG (23-126 25) . Two such hyper-sialylated molecules (D221N/C575A and 127 D221N/C309L/N297A/C575A) also bound recombinant hemagglutinin from 128 influenza A and B viruses, and disrupted influenza A-mediated agglutination 129 of human erythrocytes (24) . 
Materials and Methods 193
Production of mutants 194
The generation of glycan mutants in all combinations has been described 195 previously for the hexa-Fc that contains cysteines at both positions 309 and 196 575 (23). To make the new mutants described in Fig. 1 mutants were sequenced on both strands using previously described flanking 208 primers (23). CHO-K1 cells (European Collection of Cell Cultures) were stably 209 transfected with plasmids using FuGene (Promega), stable cell lines were 210 created, and Fc-secreting clones were expanded and proteins purified as 211 previously described (30, 31). HEK 293-F cells were transiently transfected 212 using the FreeStyle MAX293 expression system (Life Technologies) and 213 proteins purified as for CHO-K1 cells. 214
215

Size analysis using SE-HPLC 216
A SEC3000 [300 x 7.8 mm] column (Beckman) was set up on a Dionex 217 ICS3000 HPLC system and pre-equilibrated with 0.2 μm filtered PBS. Protein 218 samples at concentrations ranging from 0.5-1 mg/mL were placed in a pre-219 cooled auto-sampler at 4 o C and 10 μL of each was sequentially injected onto 220 the column. Each sample was run for 1.5 column volumes in PBS at a flow 221 rate of 0.25 mL/min. Elution was monitored at 280 and 214 nm. The column 222 was calibrated by running standard proteins (BioRad: thyroglobulin, bovine 223 IgG, ovalbumin, myoglobin and cyanocobalamin) under the same conditions. 224
Receptor and complement binding assays 225
Methods describing the binding of mutants to tetrameric human DC-SIGN 226 (Elicityl), Siglec-1, Siglec-4, and Siglec-3 (Stratech Scientific) have all been 227 described previously (30, 31). The same ELISA protocol was used for Siglec-228 2, CD23, dec-1, dec-2, clec-4a, clec-4d, MBL and MMR (Stratech Scientific or 229 Bio-Techne). Binding of C1q has been described previously (30, 31). ELISAs 230 were used to investigate binding of Fc glycan mutants to human FcγRI, 231
FcγRIIA, FcγRIIB, FcγRIIIA, and FcγRIIIB (Bio-Techne). Receptors were 232 coated down onto ELISA plates (Nunc) in carbonate buffer pH 9 (Sigma-233 Aldrich) at 2 μg/ml overnight at 4°C, unless otherwise specified. The plates 234 were blocked in PBS / 0.1% Tween-20 (PBST) containing 5% dried skimmed 235 milk. Plates were washed three times in PBST before adding Fc mutant 236 proteins at the indicated concentrations and left at 4°C overnight. Plates were 237 washed as above and incubated for 2h with 1:500 dilution of an alkaline 238 phosphatase-conjugated goat F(ab′) 2 anti-human IgG (Jackson Laboratories). 239
Plates were washed and developed for 15 min with 100 μl/well of a Sigmafast 240 p-nitrophenyl phosphate solution (Sigma-Aldrich). Plates were read at 405nm, 241 and data plotted with GraphPad Prism. 242
243
Hemagglutination inhibition assay (HIA) 244
Native influenza B Hong-Kong 5/72 was obtained from Meridian Life 245 Sciences. To determine the optimal virus-to-erythrocyte ratio, two-fold virus 246 stock dilutions were prepared in U-shaped 96-well plates (Thermo Scientific). 247
The same volume of a 1% human O+ red blood cell suspension (Innovative 248
Research) was added to each well and incubated at room temperature for 1h 249 until erythrocyte pellets had formed. After quantifying the optimal virus-to- 
Disulfide bonding and glycosylation influence the multimerization states 292 of Fc mutants expressed by HEK 293-F cells 293
Two panels of glycosylation-and cysteine-deficient mutants previously 294 expressed by CHO-K1 cells were generated in HEK 293-F cells ( Figs. 1 and  295 2). As observed with CHO-K1 cells, the HEK 293-F cells were capable of 296 making all the mutants to high yields (~30 mg/L) with the exception of the 297 N297A/N563A/C575A mutant for which we were unable to generate sufficient 298 protein for further work. Generally, all the mutants migrated on SDS-PAGE 299 with the expected molecular weights for their glycosylation or disulfide 300 bonding states ( Fig. 3) , as previously described for the same mutants 301 expressed by CHO-K1 cells (23). 302
In an earlier study with CHO-K1 cells we demonstrated that a 303 proportion of molecules in which the tailpiece Asn-563 glycan was substituted 304 for alanine ran as multimers in solution when examined by SE-HPLC (24). 305
The loss of the bulky Asn-563 glycan exposes hydrophobic amino acid 306 residues in the tailpiece that facilitate non-covalent interactions in solution. 307 Such N563A-dependent multimerization was also observed with mutants 308 expressed by HEK 293-F cells, although the proportion of multimers to 309 monomers (with the notable exception of the N563A/C575A mutant) was 310 generally lower when mutants were made by this cell line ( Fig. 4) . Clearly, the 311 choice of cell line and consequently the types of post-translational 312 modifications, dramatically impact on the biophysical properties of these 313 molecules in solution. 314
315
Fc glycan mutants expressed by HEK 293-F cells show important 316 differences in binding to glycan receptors when compared to CHO-K1 317 proteins 318
To determine the impact of the cell line on receptor binding by the two panels 319 of Fc mutants, we investigated their interaction with soluble recombinant 320 glycan receptors by ELISA ( Fig. 5 ). For most of the Fc mutants, including 321 hexa-Fc, C575A, N297A/C575A, D221N/N297A/N563A/C575A, 322 C309L/C575A, D221N/C309L/C575A, D221N/C309L/N297A/C575A and 323 D221N/C309L/N297A/N563A/C575A, expression in HEK 293-F cells reduced 324 the binding to glycan receptors when compared to equivalent molecules 325 expressed in CHO-K1 cells ( Fig. 5 ). However, two Fc mutants 326 (D221N/N563A/C575A and D221N/C309L//N573A/C575A) were notable for 327 their enhanced binding to all the glycan receptors investigated when 328 expressed in HEK 293-F cells. Given that both mutants multimerize poorly by 329 comparison to the equivalent mutants made in CHO-K1 cells (Fig. 4) , we 330 attribute this enhanced glycan receptor binding not to increased avidity effects 331 but to fine differences in the attached glycan structures. Therefore, the choice 332 of cell line can dramatically impact on the ability of individual Fc mutants to 333 interact with glycan receptors. 334
335
Fc glycan mutants expressed by HEK 293-F cells show important 336 differences in binding Fcγ-receptors compared to CHO-K1 cell proteins 337
Given the observed differences in binding to glycan receptors of the same Fc 338 mutants expressed by two different cell lines, we also tested the impact of cell 339 line on binding to the classical human FcγRs (Fig. 6 ). We investigated the nature of the N-glycans on the two panels of 384 glycosylation-and cysteine-deficient mutants by MALDI-TOF mass 385 spectrometry-based glycomic analysis (complete data set for both panels of 386 mutants provided in supplementary figures). A core-fucosylated biantennary 387 structure without antennary galactosylation, m/z 1835 (GlcNAc 4 Man 3 Fuc 1 ), is 388 the base peak of spectra from all IgG1-Fc mutants produced by HEK cells 389 ( Fig. 9 and supplementary figures) . 390
The types of site-specific glycans attached to either Asn-221, Asn-297 391 or Asn-563 could be determined using both the C575A or C309L/C575A 392 panels of mutants. For example, only sugars attached to Asn-297 are 393 available for sampling in either the N563A/C575A or C309L/N563A/C575A, 394 mutants that therefore also allow the contribution of disulfide bonding to 395 glycosylation at Asn-297 to be elucidated. 396
The N-glycosylation of Asn-297 is dominated by core-fucosylated bi-397 antennary glycans (m/z 1835 and 2040) with varied galactosylation levels 398 (Gal 0-2 GlcNAc 4 Man 3 Fuc 1 ), and a Man 5 GlcNAc 2 (m/z 1579) high mannose 399 structure is also observed (Fig. 9B ). The Asn-563 N-glycans are much more 
Fc glycan mutants expressed in HEK 293-F cells are less sialylated than 425 the equivalent mutants expressed in CHO-K1 cells 426 427
Site-specific levels of sialylation were semi-quantitatively assessed for both 428 panels of mutants and compared to levels seen in the equivalent mutants 429 expressed in CHO-K1 cells (Fig. 10) . Although levels of sialylated glycans 430 attached at positions Asn-297 (the N563A/C575A mutant) and Asn-563 (the 431 N297A/C575A mutant) are similar for both cell lines (Fig. 10) To test if the choice of cell line affected the functionality of the two panels of 446 mutant Fcs, we used the World Health Organization (WHO) hemagglutination 447 inhibition assay (HIA) to quantify the inhibitory titers for each mutant against 448 an influenza B virus (Fig. 11 ). As shown previously with an avian influenza A 449 (H1N1) (24), mutants containing Asn-221 hinge-attached glycans, and in 450 particular the D221N/C309L/N297A/C575A mutant, prevented 451 hemagglutination by an influenza B virus at concentrations as low as 30nM, 452 an eight-fold improvement over equimolar IVIG or polyclonal anti-influenza B 453 antisera (Fig. 11) . In stark contrast, the same mutants expressed by HEK 293-454 F cells were unable to inhibit hemagglutination by either influenza A (not 455 shown) or influenza B virus (Fig. 11 ). This shows that the functional potential 456 of individual glycan-modified Fc mutants is dependent on the choice of cell 457 line used for their manufacture. 458
Discussion 459
We have shown using CHO-K1 cells that the structure and effector function of 460 human IgG1-Fc can be profoundly altered by the addition or removal of N-461 linked glycosylation (23, 24). For example, we could show that Fc fragments 462 containing complex biantennary glycans attached to both the N-and C-463 terminal ends of the Fc could inhibit influenza A-mediated agglutination of 464 human erythrocytes (24). The aim of the current study was to reveal possible 465 variation in functional glycosylation related to differences in two host cell lines, 466 CHO-K1 and HEK 293-F, particularly as antibodies and Fc fusions are the 467 fastest growing therapeutic class in the pharmaceutical industry (26, 37, 38). 468 Two intriguing aspects of N-linked glycosylation are relevant to this 469 study. First, the differential binding seen to human glycan ( Fig. 5 ) and Fcγ 470 ( Fig. 6 ) receptors between the same mutants expressed by two different cell 471 lines. These differentially manufactured mutants now need to be compared in 472 relevant in vivo disease models where the Fc is therapeutically useful, given 473 that differential sialic acid linkages, α2,6 and α2,3, are known to impact on the 474 anti-inflammatory properties of the Fc (39, 40). Such nuanced glycosylation 475 may also explain why the therapeutic efficacy of molecules generated by 476 different expression systems, and subsequently tested in different animal 477 models, do not always translate to efficacy in human studies (41). 478 Second, we have studied the exquisite impact of the host cell line on 479 the efficacy of sialylated Fcs to inhibit influenza viruses (Fig. 11 ). One 480 possible explanation is that overall sialylation levels for all the influenza 481 blocking mutants, in particular the D221N/C309L/N297A/C575A mutant, are 482 approximately five-fold lower when expressed by HEK 293-F cells (Fig. 10) . 483
However, overall level of sialylation is not the only possible explanation for the 484 relative efficacy of the CHO-K1 mutants in inhibiting influenza virus 485 hemagglutination, as the CHO-K1-expressed D221N/C575A mutant also 486 contained approximately five-fold less sialyation than the 487 D221N/C309L/N297A/C575A mutant made in the same cell line (Fig. 10) . 488
This indicates that the fine specificity (e.g. α2,3 vs. α2,6 linkages) of these 489 sialylated glycans may also be a contributing factor to their efficacy. 490
As demonstrated previously for influenza A (24), binding and inhibition 491 of influenza B viruses is stronger with mutants containing Asn-221, and in 492 particular by the monomeric mutant D221N/C309L/N297A/C575A in which the 493 N-and C-terminal sialylated sugars are spaced ~60Å apart (Figs. 11 and 494 (24)). Recent biophysical studies with alternative glycan-decorated scaffolds 495 have shown that ~1,000 fold enhancements over monovalent binding to HA 496 can be achieved with only two sialylated ligands, provided the sugars are 497 arranged 50-100Å apart (42, 43). As we also observed with Fc multimerizing 498 mutants from panel 1, no additional benefit with respect to virus neutralization 499 was gained with larger, more complex sialylated structures ( Fig. 11, and as 500 seen with the D221N/N297A/N563A/C575A mutant). 501
We do not yet know if sialylated Fcs are susceptible to cleavage by the 502 viral neuraminidase. Although a decoy for NA may be a therapeutically 503 attractive strategy (44), we have not observed a direct decay in the HIA after 504 prolonged incubation. This suggests that the high specific avidity of these 505 molecules for HA may reduce their susceptibility to NA, a hypothesis that fits 506 with the relatively low efficiency of neuraminidase (k cat = 30-155 s-1 ), together 507 with the asymmetric distribution of NA in relation to HA on the surface of 508 filamentous influenza viruses (45-47). 509
In order to be useful compounds when administered intranasally, or as 510 an aerosol, the sialylated Fc needs to out-compete sialylated mucins that 511 viruses use through ratchet-like interactions with HA and NA to migrate to the 512 underlying respiratory epithelium (45). Of the 15 known human mucins in the 513 human lung, only MUC5 has been shown to protect from influenza (48, 49) . HEK 293-F cells that attach more human type α2,6-linked sialic acid (Fig. 10) . 520
The apparent importance of α2,3-linked N-glycans to inhibition of both 521 influenza A and B by the CHO-K1 Fc mutants indicates that viruses can 522 evolve away from inhibition by mucus whose predominant O-linked glycans 523 are mostly α2,6-linked. Our working hypothesis is that HEK-expressed 524 compounds may therefore inhibit influenza viruses that circulate in human 525 populations or that are propagated in cell lines that attach more human-like 526 α2,6-linked sialic acid. I V I G a n t i -i n f l u e n z a B v e c o n t r o l 1 0 1 1 1 2 1 3 1 5 1 6 1 7 1 8 1 4 Fig. 11 
